section name header

Indications ⬇

REMS


Contraind./Precautions ⬆ ⬇

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects ⬆ ⬇

CNS: SEIZURES, headache, dizziness

EENT: visual abnormalities

CV: hypotension, thromboembolism, thrombosis

GI: diarrhea, nausea, vomiting

MS: pain

Misc: POANAPHYLAXIS

Interactions ⬆ ⬇

Drug-drug:

Availability ⬆ ⬇

(Generic available)

Route/Dosage ⬆ ⬇

Renal Impairment

Renal Impairment

US Brand Names ⬆ ⬇

Cyklokapron, Lysteda

Action ⬆ ⬇

  • Inhibits activation of plasminogen, thereby preventing the conversion of plasminogen to plasmin.
Therapeutic effects:
  • Decreased bleeding following dental surgery in hemophiliacs.
  • Reduced need for replacement therapy.
  • Reduced menstrual blood loss.

Classifications ⬆ ⬇

Therapeutic Classification: hemostatic agents

Pharmacologic Classification: antifibrinolytics, plasminogen inactivators

Pharmacokinetics ⬆ ⬇

Absorption: 100% bioavailable with IV administration; 45% bioavailability after oral administration.

Distribution: Penetrates readily into joint fluid and synovial membranes.

Metabolism/Excretion: 95% excreted unchanged in urine.

Half-Life: 2 hr (IV) (↑ in renal impairment); 11 hr (PO).

Time/Action Profile ⬆ ⬇

(blood levels)

ROUTEONSETPEAKDURATION
IVunknownunknown7–8 hr
POunknown2.5 hrunknown

Patient/Family Teaching ⬆ ⬇

Pronunciation ⬆ ⬇

tran-ex-AM-ikAS -id

Code ⬆

NDC Code